

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4343051

| | |
|---|--------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| ZHAOLIN WANG | 03/19/2017 |
| PING YE | 03/16/2017 |
| ALONSO RICARDO | 03/16/2017 |
| KRISTOPHER JOSEPHSON | 03/20/2017 |
| PAUL ANDERSON | 03/17/2017 |
| MICHELLE DENISE HOARTY | 03/16/2017 |
| ZHONG MA | 03/16/2017 |
| NATHAN EZEKIEL NIMS | 03/17/2017 |
| EBERHARD SCHNEIDER | 03/22/2017 |
| GREGOR SCHURMANN | 03/26/2017 |
| PETER WAGNER | 03/22/2017 |
| DOUGLAS A TRECO | 03/16/2017 |
| HONG ZHENG | 03/17/2017 |
| DANIEL ELBAUM | 03/20/2017 |
| NICOLAS CEDRIC BOYER | 03/21/2017 |
| RECEIVING PARTY DATA | |
| Name: | RA PHARMACEUTICALS, INC. |
| Street Address: | 87 CAMBRIDGE PARK DRIVE |
| City: | CAMBRIDGE |
| State/Country: | MASSACHUSETTS |
| Postal Code: | 02140 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 15459035 |
| CORRESPONDENCE DATA | |
| Fax Number: | (978)448-8721 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 978-448-8720 |

| | |
|----------------------------|-----------------------------|
| Email: | docketing@dtwardlaw.com |
| Correspondent Name: | DT WARD, PC |
| Address Line 1: | 142A MAIN STREET |
| Address Line 4: | GROTON, MASSACHUSETTS 01450 |

| | |
|--------------------------------|-----------------------|
| ATTORNEY DOCKET NUMBER: | 2011.1001USCON2 |
| NAME OF SUBMITTER: | JESSICA L. CHARLAND |
| SIGNATURE: | /Jessica L. Charland/ |
| DATE SIGNED: | 03/29/2017 |

Total Attachments: 12

source=2011.1001USCON2_Assignment#page1.tif
source=2011.1001USCON2_Assignment#page2.tif
source=2011.1001USCON2_Assignment#page3.tif
source=2011.1001USCON2_Assignment#page4.tif
source=2011.1001USCON2_Assignment#page5.tif
source=2011.1001USCON2_Assignment#page6.tif
source=2011.1001USCON2_Assignment#page7.tif
source=2011.1001USCON2_Assignment#page8.tif
source=2011.1001USCON2_Assignment#page9.tif
source=2011.1001USCON2_Assignment#page10.tif
source=2011.1001USCON2_Assignment#page11.tif
source=2011.1001USCON2_Assignment#page12.tif

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Ra Pharmaceuticals, Inc., having a place of business at 87 Cambridge Park Drive, Cambridge, Massachusetts 02140, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 15/459,035, entitled "PEPTIDE AND PEPTIDOMIMETIC INHIBITORS" filed on March 15, 2017.

2. The entire worldwide right, title, and interest in and to:
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

Filed: March 15, 2017

Application No.: 15/459,035

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.


Date _____

Signature _____
Name Zhaolin Wang


Date 3/16/17

Signature 
Name Ping Ye

Date 03/16/17

Signature 
Name Alonso Ricardo

Date 3/20/17

Signature 
Name Kristopher Josephson

Date _____

Signature _____
Name Paul Anderson

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
Filed: March 15, 2017
Application No.: 15/459,035

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date 3/19/2017 Signature 
Name Zhaolin Wang

Date 3/16/17 Signature 
Name Ping Ye

Date 03/16/17 Signature 
Name Alonso Ricardo

Date _____ Signature _____
Name Kristopher Josephson

Date _____ Signature _____
Name Paul Anderson

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

Filed: March 15, 2017

Application No.: 15/459,035

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.


This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date _____

Signature _____


Name Zhaolin Wang

Date 3/16/17

Signature 

Name Ping Ye

Date 03/16/17

Signature 

Name Alonso Ricardo

Date _____

Signature _____

Name Kristopher Josephson

Date 3/17/2017

Signature 

Name Paul Anderson

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

Filed: March 15, 2017

Application No.: 15/459,035

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date _____ Signature _____
Name Zhaolin Wang

Date 3/16/17 Signature _____
Name Ping Ye


Date 03/16/17 Signature _____
Name Alonso Ricardo

Date _____ Signature _____
Name Kristopher Josephson

Date _____ Signature _____
Name Paul Anderson

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
Filed: March 15, 2017
Application No.: 15/459,035

Date 3/16/17 Signature 
Name Michelle Denise Hoarty


Date 3/16/17 Signature 
Name Zhong Ma


Date _____ Signature _____
Name Nathan Ezekiel Nims

Date _____ Signature _____
Name Eberhard Schneider

Date _____ Signature _____
Name Gregor Schurmann

Date _____ Signature _____
Name Peter Wagner

Date 3/16/17 Signature 
Name Douglas A. Treco

Date 03/17/2017 Signature 
Name Hong Zheng

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
Filed: March 15, 2017
Application No.: 15/459,035

Date 3/16/17

Signature

Name Michelle Denise Hoarty

Date 3/16/17

Signature

Name Zhong Ma

Date _____

Signature

Name Nathan Ezekiel Nims

Date _____

Signature

Name Eberhard Schneider

Date _____

Signature

Name Gregor Schurmann

Date 3/22/17

Signature

Name Peter Wagner

Date 3/16/17

Signature

Name Douglas A. Treco


Date _____


Signature

Name Hong Zheng

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
Filed: March 15, 2017
Application No.: 15/459,035

Date 3/16/17 Signature 
Name Michelle Denise Hoarty


Date 3/16/17 Signature 
Name Zhong Ma

Date 3/17/17 Signature 
Name Nathan Ezekiel Nims

Date _____ Signature _____
Name Eberhard Schneider

Date _____ Signature _____
Name Gregor Schurmann

Date _____ Signature _____
Name Peter Wagner

Date 3/16/17 Signature 
Name Douglas A. Treco

Date _____ Signature _____
Name Hong Zheng

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS

Filed: March 15, 2017

Application No.: 15/459,035

Date 3/16/17

Signature


Name


Michelle Denise Hoarty

Date 3/16/17

Signature

Name


Zhong Ma

Date _____

Signature

Name

Nathan Ezekiel Nims

Date _____

Signature

Name

Eberhard Schneider

Date 3/26/17

Signature

Name


Gregor Schurmann

Date _____

Signature


Name

Peter Wagner

Date 3/16/17

Signature

Name


Douglas A. Treco

Date _____


Signature

Name


Hong Zheng

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
Filed: March 15, 2017
Application No.: 15/459,035

Date 3/16/17 Signature 
Name Michelle Denise Hoarty


Date 3/16/17 Signature 
Name Zhong Ma

Date _____ Signature _____
Name Nathan Ezekiel Nims

Date 3/22/2017 Signature 
Name Eberhard Schneider

Date _____ Signature _____
Name Gregor Schurmann

Date _____ Signature _____
Name Peter Wagner

Date 3/16/17 Signature 
Name Douglas A. Treco

Date _____ Signature _____
Name Hong Zheng

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
Filed: March 15, 2017
Application No.: 15/459,035

Date 3/20/17

Signature 
Name Daniel Elbaum

Date _____

Signature _____
Name Nicolas Cedric Boyer

Title: PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
Filed: March 15, 2017
Application No.: 15/459,035

Date _____

Signature _____

Name Daniel Elbaum

Date 03/21/2017

Signature _____

Name Nicolas Cedric Boyer